Globes Online is reporting that KarmelSonix Ltd., an Australian owned company, has received FDA approval for its latest diagnostic system which listens to the wheezing sounds asthmatics make while breathing, analyzes their signatures, and provides feedback whether particular sounds indicate a more acute condition. Audio sensors are worn around the neck and chest, and are connected to the proprietary WIM-PC platform, which does the audio analysis.
From the company site:
It is KS’ [KarmelSonix] aim to provide novel tools for Acoustic Asthma Management to the clinical market. It is doing so by providing a simple, yet highly accurate and relevant measure of asthma – the Wheeze Rate (Wz%). When coupled with measuring the Cough Count, the Wz% is an objective and quantitative indicator of the extent of the airway narrowing at any given moment. It is calculated as the duty cycle of wheeze activity as % of the elapsed time and as such should be controlled at nearly zero by proper treatment during day and night. Obtaining the Wz% only requires that the patient will breathe at the rate and depth of convenience. No imposition is made on the patient and no cooperation is needed. KS’is set forth to provide a full range of products, all based on its core technology, but implemented in the configuration that is most appropriate for its use – from the patient’s home all the way to the Intensive Care Unit.